The serum tryptase test: an emerging robust biomarker in clinical hematology
Year: 2014
Type: review
Abstract: During the past few years, a number of molecular markers have been developed in clinical hematology, most of them related to specific gene defects. However, there is also an unmet need to develop novel serologic parameters to improve diagnostics and prognostication in daily practice. Among these, the serum tryptase appears to be a most reliable biomarker of myeloid neoplasms. Elevated tryptase levels are found in subgroups of patients with mastocytosis, myelodysplastic syndrome, myeloproliferative neoplasm, acute myeloid leukemia, chronic myeloid leukemia and chronic eosinophilic leukemia. In these patients, the tryptase level is of diagnostic and/or prognostic significance. In mastocytosis, an elevated tryptase level is a minor criterion of systemic disease and in BCR-ABL1(+) chronic myeloid leukemia, elevated tryptase at diagnosis correlates with treatment responses and overall survival. In patients with elevated tryptase, the enzyme also serves as follow-up parameter and can be employed to measure treatment-responses. In the current article, we review and update the perspectives of tryptase and provide recommendations for use of this conventional biomarker in daily practice.
Source: Expert Review of Hematology
Institutions: Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Pathologisches Institut, Ludwig-Maximilians-Universität München, Heidelberg University, Medizinische Fakultät Mannheim, Brigham and Women's Hospital, Harvard University, Stanford Cancer Institute, Stanford University, École Normale Supérieure Paris-Saclay, Centre National de la Recherche Scientifique, Laboratoire de Biologie et Pharmacologie Appliquée
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2140307679